Novel predictors of responsiveness to CAR T-cell therapy
TS-075167 — PROBLEM
CAR T-cell therapy against CD19 has become the standard of care for relapsed/refractory B-cell non-Hodgkin lymphoma (NHL), the most common kind of lymphoma. Recent studies have identified clinical risk factors for prediction of CAR T therapy failure; however, these risk factors are inconsis…
- College: College of Medicine (COM)
- Inventors: Yang, Yiping; Denlinger, Nathan
- Licensing Officer: He, Panqing
